CLINICAL TRIALS PROFILE FOR NELFINAVIR MESYLATE

All Clinical Trials for NELFINAVIR MESYLATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000859 ↗	A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 [AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3]. To compare NFV with RTV for the development of adverse events and for rates of permanent discontinuation of study medication. [AS PER AMENDMENT 10/02/97: To compare by intention-to-treat analysis for disease progression, including death, the following two regimens: NFV plus background combination antiretroviral (AR) therapy followed by indinavir (IDV) or RTV in the event of significant intolerance; and RTV plus AR therapy followed by IDV, then NFV, in the event of significant intolerance.] [AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: To determine the relative rates of emergence of HIV-1 resistance and to compare changes in plasma HIV RNA levels and CD4+ cell counts in a sample of patients with CD4+ cell counts
NCT00000872 ↗	Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1969-12-31	This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.
NCT00000872 ↗	Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.
NCT00000885 ↗	Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). To evaluate the safety and tolerability of these treatment arms. [AS PER AMENDMENT 06/16/99: To compare the time to confirmed treatment failure, permanent discontinuation of treatment, or death between the treatment arms.] [AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable.] Group B: To compare the proportion of patients who achieve plasma HIV-1 RNA concentrations below 500 copies/ml, as assessed by the standard Roche Amplicor assay at Week 16, or to compare the absolute changes in plasma HIV-1 RNA concentrations at Week 16 across the treatment arms: ABC or approved nucleoside analogs and nelfinavir (NFV) or placebo in combination with efavirenz (EFV) and adefovir dipivoxil. To compare the safety and tolerability of these treatment arms. Group C: To monitor plasma HIV-1 RNA trajectory over time and determine the time to a confirmed plasma HIV-1 RNA concentration above 2,000 copies/ml on 2 consecutive determinations for patients treated with ZDV or stavudine (d4T) plus 3TC and IDV. Group D: To evaluate plasma HIV-1 RNA responses at Weeks 16 and 48. To evaluate the safety and tolerability of the treatment arms: ABC, EFV, adefovir dipivoxil, and NFV. This study explores new treatment options for ACTG 320 enrollees (and, if needed, a limited number of non-ACTG 320 volunteers) who have been receiving ZDV (or d4T) plus 3TC and IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, nonsequential cohorts (Groups A, B, C, D), different approaches to evaluating virologic success, i.e., undetectable plasma HIV-1 RNA levels, and virologic failure, i.e., plasma HIV-1 RNA levels of 500 copies/ml or more [AS PER AMENDMENT 12/27/01: 200 copies/ml or more], are explored while maintaining long-term follow-up of ACTG 320 patients. [AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable. This study will examine the question of whether intensification of therapy can prolong the virologic benefit in individuals whose plasma HIV-1 RNA concentrations have been below the limits of assay detection on ZDV (or d4T) plus 3TC plus IDV.]

Clinical Trial Conditions for NELFINAVIR MESYLATE

Condition Name

Condition Name for NELFINAVIR MESYLATE
Intervention	Trials
HIV Infections	74
Mycobacterium Avium-Intracellulare Infection	2
Lipodystrophy	2
Pregnancy	2

Condition MeSH

Condition MeSH for NELFINAVIR MESYLATE
Intervention	Trials
HIV Infections	74
Infections	18
Infection	17
Acquired Immunodeficiency Syndrome	12

Clinical Trial Locations for NELFINAVIR MESYLATE

Trials by Country

Trials by Country for NELFINAVIR MESYLATE
Location	Trials
United States	702
Puerto Rico	19
Canada	18
Switzerland	3
Italy	3

Trials by US State

Trials by US State for NELFINAVIR MESYLATE
Location	Trials
California	63
New York	44
Pennsylvania	38
Florida	36
Texas	34

Clinical Trial Progress for NELFINAVIR MESYLATE

Clinical Trial Phase

Clinical Trial Phase for NELFINAVIR MESYLATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 3	14

Clinical Trial Status

Clinical Trial Status for NELFINAVIR MESYLATE
Clinical Trial Phase	Trials
Completed	71
Unknown status	5
Terminated	4

Clinical Trial Sponsors for NELFINAVIR MESYLATE

Sponsor Name

Sponsor Name for NELFINAVIR MESYLATE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	31
Agouron Pharmaceuticals	14
Glaxo Wellcome	9

Sponsor Type

Sponsor Type for NELFINAVIR MESYLATE
Sponsor	Trials
NIH	49
Industry	48
Other	17

NELFINAVIR MESYLATE Market Analysis and Financial Projection

Last updated: April 23, 2026

Nelfinavir Mesylate: Clinical Trials Update, Market Analysis, and Projections

What is nelfinavir mesylate and where does it sit in the clinical pipeline?

Nelfinavir mesylate is an HIV-1 protease inhibitor (PI) that has been in clinical use since the mid-1990s and is no longer a first-line standard of care in most contemporary regimens. Current public trial activity is limited, and recent trial disclosures focus on historical comparison sets, combination strategy exploration, or mechanistic/virology questions rather than broad phase-advancement programs.

Regimen context (HIV):

• Nelfinavir (NFV) is a PI class drug; modern HIV therapy commonly uses boosted PIs or integrase inhibitors (INSTIs) due to better tolerability, dosing convenience, and resistance profiles in many settings.
• As a result, Nelfinavir’s commercial and development posture has shifted from “new product expansion” to “niche or life-cycle optimization,” with trial activity that is sparse relative to newer agents.

Public clinical trial landscape (directionally):

• The active pipeline for Nelfinavir itself is limited, with fewer late-stage (phase 2/3) trials than earlier years.
• Trial activity that does appear is typically small, specific to particular questions (viral dynamics, resistance mechanisms, pharmacology in defined populations), and less likely to drive regulatory label expansion.

What do the main trial sources show about ongoing or recent activity?

A complete and actionable trial-by-trial update requires current, trial-relevant records (study status, start/completion dates, endpoints, arms, and results). Those data are not provided in the information available here, and producing a fabricated or incomplete trial table would violate accuracy requirements.

What can be stated with precision from widely used public trial registries is the classification of nelfinavir’s current commercial position: the drug is not associated with broad, ongoing late-stage pivotal programs in the way it would be if a new indication or formulation were under active phase expansion. This aligns with the observed shift in HIV development priorities toward newer therapeutic classes and updated PI strategies.

Implication for investors and R&D:

• Expect development value primarily from formulation, access, and brand lifecycle rather than a near-term label expansion driven by fresh phase-3 readouts.
• Forecasting future clinical impact should be anchored to availability trends and competitive dynamics rather than assuming a new pivotal program.

---

Where is the market today, and what drives demand for nelfinavir?

How does nelfinavir demand behave versus modern HIV treatment standards?

Nelfinavir is used under conditions that are shaped by:

• Historical prescribing patterns in certain markets
• Formulary inclusion in specific cohorts
• Line of therapy choices when newer regimens are unsuitable or unavailable
• Patent and generic availability dynamics

Because the drug is older, market demand is driven less by “new starts” and more by:

• Treatment continuation where already prescribed
• Substitution after regimen switches in constrained formularies
• Regional access and procurement practices

What supply and pricing forces matter most?

For an established HIV product like nelfinavir, price and share are primarily influenced by:

• Generic entry and volume contracts
• Wholesale channel economics
• Public-sector procurement tender cycles
• Competition from newer PIs and INSTIs

Key commercial reality: as HIV regimens increasingly center on INSTI-based combinations, the PI segment share can dilute over time even if the absolute number of treated patients grows.

---

What is the projection for nelfinavir mesylate revenue and share?

Projection framework (what to model)

A defensible projection for a mature HIV agent should be modeled on:

• Treated population growth (global HIV prevalence under ART)
• Share shift away from older PIs to newer classes
• Generic price erosion
• Region-specific procurement durability (public tender schedules can stabilize volumes even as branded share falls)
• Line-of-therapy distribution (older PIs tend to decline in “preferred first-line” roles)

Expected directionality over a 3 to 7 year horizon

Given the drug’s age and class evolution in HIV care:

• Unit volumes: slowly declining or flat in markets where first-line shifted away from non-INSTI options, with pockets of stability in constrained settings.
• Revenue: declining in value terms due to generic pricing pressure and regimen preference shift.
• Share: gradual erosion as new initiations prefer newer regimens.

Practical investor takeaway: the highest-probability outcomes are “slow decline with regional pockets” rather than “inflection via clinical expansion.”

---

Competitive positioning: how does nelfinavir compare to dominant HIV classes?

Why substitution risk is structurally high

Even without new phase-3 readouts, substitution risk remains elevated because:

• Contemporary guidelines often favor regimens with better tolerability, lower pill burden, and higher barriers to discontinuation.
• INSTI-based regimens generally dominate initial treatment choices in most guidelines and formularies.
• PI use increasingly concentrates in specific resistance patterns, contraindications, or regimen failures.

What competitive products most constrain nelfinavir?

Across most geographies, the main competitive pressure typically comes from:

• INSTI-based backbones (dominant first-line and large switching pool)
• Newer PIs with more convenient dosing or resistance advantages
• Fixed-dose combination strategies that improve adherence

---

What are the most actionable business implications?

For R&D

• Treat nelfinavir as a life-cycle and access program, not a label-expansion bet, unless a credible new use-case emerges with strong differentiation.
• If resources are allocated, they should target either formulation improvements, manufacturing cost reduction, or niche pharmacology studies that can protect or extend access.

For investments

• Base-case financial models should assume erosion in branded share and pricing, with stabilization in select procurement markets.
• Upside is limited unless a specific region exhibits unusually durable tender cycles or a unique patient cohort dependence on older PIs.

---

Key Takeaways

• Nelfinavir mesylate is a mature HIV protease inhibitor with limited contemporary phase-expansion activity and no clear basis for near-term label-driven market expansion.
• Market demand is increasingly shaped by generic supply dynamics, formulary inclusion, and procurement cycles rather than new clinical uptake.
• Revenue and share projections should assume gradual erosion in line with global shifts toward INSTI-centric regimens, with possible stability in constrained access settings.

---

FAQs

1. Is nelfinavir mesylate still being actively developed for new indications?
   The current posture is consistent with limited late-stage expansion activity relative to newer HIV drug classes.

2. What drives remaining use of nelfinavir in the market?
   Continued treatment in patients already on therapy, formulary constraints, and regional procurement choices.

3. How should a revenue forecast for nelfinavir be structured?
   Model ART population growth plus line-of-therapy shifts away from older PIs, layered with generic price erosion and tender-driven volume stability.

4. What is the biggest market risk for nelfinavir?
   Ongoing substitution as guidelines and formularies keep favoring INSTI-based regimens and newer PI strategies.

5. What R&D investments have the highest probability of commercial impact?
   Cost-down manufacturing, supply continuity, and targeted formulation work aligned to access and procurement needs rather than assuming a pivotal label expansion.

---

References

[1] ClinicalTrials.gov. (n.d.). Nelfinavir mesylate studies. https://clinicaltrials.gov
[2] U.S. Food and Drug Administration. (n.d.). Nelfinavir (protease inhibitor) drug information and labeling history. https://www.fda.gov
[3] World Health Organization. (n.d.). Consolidated HIV treatment guidelines (updates and regimen positioning). https://www.who.int/hiv